AstraZeneca, a pharmaceutical giant headquartered in Cambridge, England, reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA) to supply vaccines currently being tested by the University of Oxford to Germany, France, Italy, and the Netherlands “at no profit.”
Oxford University is currently doing phase two and phase three trials of the vaccine in about 10,000 adult volunteers.
“This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s